RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
-14.02%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.99B
AUM Growth
-$1.53B
(-20%)
Cap. Flow
-$57.7M
Cap. Flow
% of AUM
-0.96%
Top 10 Holdings %
Top 10 Hldgs %
62.92%
Holding
100
New
11
Increased
14
Reduced
4
Closed
15
Top Buys
| 1 |
Vaxcyte
PCVX
|
$132M |
| 2 |
SION
Sionna Therapeutics, Inc. Common Stock
SION
|
$109M |
| 3 |
Disc Medicine
IRON
|
$78.3M |
| 4 |
Geron
GERN
|
$48.3M |
| 5 |
89bio
ETNB
|
$41.5M |
Top Sells
| 1 |
Legend Biotech
LEGN
|
$244M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$111M |
| 3 |
Axsome Therapeutics
AXSM
|
$84.6M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$82.1M |
| 5 |
Praxis Precision Medicines
PRAX
|
$58.6M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEPN
26
Septerna, Inc. Common Stock
SEPN
$652M
| $40.5M | 0.68% |
6,995,858
| – | – |
|
27
Tourmaline Bio
TRML
$745M
| $38.6M | 0.64% |
2,538,925
| – | – |
|
|
CLYM
28
Climb Bio, Inc. Common Stock
CLYM
$167M
| $38.3M | 0.64% |
31,419,267
| – | – |
|
29
Scholar Rock
SRRK
$3.05B
| $36.5M | 0.61% |
1,136,453
+1,118,837
| +6,351% | +$36M |
|
30
UroGen Pharma
URGN
$917M
| $35.5M | 0.59% |
+3,206,271
| New | +$35.5M |
|
|
ARTV
31
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76M
| $29.6M | 0.49% |
9,853,302
| – | – |
|
32
Fulcrum Therapeutics
FULC
$393M
| $29.5M | 0.49% |
10,229,099
| – | – |
|
33
Vor Biopharma
VOR
$255M
| $28.4M | 0.48% |
39,646,039
| – | – |
|
34
Astria Therapeutics
ATXS
$411M
| $27.3M | 0.46% |
5,105,213
| – | – |
|
35
Kura Oncology
KURA
$712M
| $26.4M | 0.44% |
4,004,610
-446,431
| -10% | -$2.95M |
|
36
Structure Therapeutics
GPCR
$1.23B
| $26.3M | 0.44% |
1,517,418
| – | – |
|
37
Cidara Therapeutics
CDTX
$1.59B
| $23.5M | 0.39% |
1,092,796
| – | – |
|
|
JBIO
38
Jade Biosciences, Inc. Common Stock
JBIO
$246M
| $23.1M | 0.39% |
262,631
| – | – |
|
39
IDEAYA Biosciences
IDYA
$2.07B
| $22.1M | 0.37% |
1,347,252
| – | – |
|
|
ITOS
40
DELISTED
iTeos Therapeutics
ITOS
| $21.8M | 0.36% |
3,649,057
+1,556,798
| +74% | +$9.29M |
|
41
Travere Therapeutics
TVTX
$1.88B
| $20.6M | 0.34% |
1,150,000
| – | – |
|
42
Nkarta
NKTX
$146M
| $19.9M | 0.33% |
10,805,129
| – | – |
|
43
Glaukos
GKOS
$5.3B
| $18.7M | 0.31% |
+190,256
| New | +$18.7M |
|
44
Monopar Therapeutics
MNPR
$260M
| $18.6M | 0.31% |
511,207
| – | – |
|
|
MTSR
45
Metsera, Inc. Common Stock
MTSR
$3.73B
| $18.4M | 0.31% |
+675,525
| New | +$18.4M |
|
46
EyePoint Pharmaceuticals
EYPT
$965M
| $17.2M | 0.29% |
3,181,818
| – | – |
|
47
10x Genomics
TXG
$1.72B
| $17M | 0.28% |
1,944,247
-1,335,154
| -41% | -$11.7M |
|
48
Acrivon Therapeutics
ACRV
$57.2M
| $16.9M | 0.28% |
8,340,508
| – | – |
|
49
Enliven Therapeutics
ELVN
$1.21B
| $16.7M | 0.28% |
848,986
| – | – |
|
50
Acumen Pharmaceuticals
ABOS
$84.8M
| $16.4M | 0.27% |
14,932,063
| – | – |
|